Killian Meara

A model showed that if a vaccine coverage of 66% were achieved—similar to flu vaccination coverage—it could have a budget impact of $6.48 to $6.78 billion over the first RSV season.

A new study found that 16.1% of patients treated with nirmatrelvir-ritonavir (Paxlovid) reported long COVID symptoms, compared to 14% of untreated patients.

Patients on a moderate carbohydrate diet increased their time in range by 4.7% and decreased their time above range by 5.9%.

The vaccine, called mRNA-1345, demonstrated an efficacy of 83.7% against RSV-associated lower respiratory tract disease with at least 2 signs or symptoms and 82.4% against the disease with at least 3 signs or symptoms.

Higher concentrations of omega-3 fatty acids were associated with the ability to exchange carbon dioxide more efficiently and longer transplant-free survival.

The nonprofit pharmaceutical company plans to begin fulfilling orders for RiVive more broadly in early 2023 and will make it available across the US for free of charge or at a low breakeven cost.

Patients hospitalized for either virus had an increased risk of death, hospital readmission, and health problems in multiple organ systems over 18 months of follow-up.

The federal agency also removed the maximally tolerated qualifier for statin use and the prior cardiovascular morbidity and mortality limitation of use statement.

Three posters presented at the 65th American Society of Hematology Annual Meeting and Exposition looked into the efficacy and safety of the therapies.

Six posters presented at the 65th American Society of Hematology Annual Meeting and Exposition looked at how treatments are impacting care for this patient population.

A Q&A with Robert Walker, MD, senior vice president and chief medical officer at Novavax.

A recent study found that cannabis exposure over the course a pregnancy was associated with small-for-gestational-age birth, medically indicated preterm birth, stillbirth, or hypertensive disorders of pregnancy.

Three posters presented at ASHP Midyear 2023 delved deeper into the topic of antimicrobial stewardship programs and their impact on antibiotic resistance.

Two posters presented at ASHP Midyear 2023 looked at how the two medications differed and how clinical pharmacy services improved transitions.

A Q&A with Kevin Malloy, PharmD, BCPS, on how diabetes technology has improved and how it can help pregnant people manage their disease.

Two posters presented at ASHP 2023 Midyear examined how accurate answers were from the artificial intelligence chatbot.

A study presented at ASHP Midyear 2023 found that primary care physicians said a refill management service helped reduce burnout and improved the quality of patient care.

A Q&A with Lisa McCabe, PharmD, MBA, BSN, director of Health System Pharmacy at Cardinal Health.

Updated guidance from the United States Preventive Services Task Force advises against low-dose aspirin use as a primary prevention of atherosclerotic cardiovascular disease in certain populations who have bleeding risks.

An evaluative study on an open resource Instagram page that provides information on new medications to pharmacists was recently presented at the American Society of Health-System Pharmacists 2023 Midyear Clinical Meeting and Exhibition.

A new study found that glucose monitoring devices can help significantly improve the sleep of both parents and children.

A Q&A with Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, director of education and training in diabetes technology at the Cleveland Clinic.

Federal guidance from the United States Pharmacopeia characterizes the practice as drug compounding, which pharmacists fear may drive up prices.

A new systematic review and meta-analysis found that the risk of type 2 diabetes decreased significantly at walking speeds of 4 km/h or above.

The World Cancer Research Fund (WCRF) and American Institute for Cancer Research (AICR) Cancer Prevention Recommendations were updated in 2018 and encourage adopting healthy lifestyle habits.

A new study found that models that included wastewater data were 15% more accurate when compared to models that only included clinical case data.

A new study found that over 90% of patients and providers said they found the continuous glucose monitoring useful.

In counties with poor land quality, particularly urban counties, there was a higher incidence of early-stage disease and total breast cancer.

The capsule was developed by the pharmaceutical company Lupin and is a generic equivalent to Boehringer Ingelheim’s Spiriva HandiHaler.

An analysis on the Diabetes Prevention Program in England found it was effective at improving key cardiovascular risk factors, including glycated hemoglobin and excess body weight.